PRNAF 0.05 Alterity Therapeutics Limited
| Range: | 2.0E-4-0.0068 | Vol Avg: | 211 | Last Div: | 0 | Changes: | 0 |
| Beta: | 0.68 | Cap: | 0.02B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Tue Sep 25 2012 | Empoloyees: | 10 | ||
| CUSIP: | CIK: | 0001131343 | ISIN: | AU0000043945 | Country: | AU | |
| CEO: | Dr. David A. Stamler M.D. | Website: | https://alteritytherapeutics.com | ||||
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow